Kyverna Therapeutics Inc. (NASDAQ: KYTX) Stock Information | RedChip

Kyverna Therapeutics Inc. (NASDAQ: KYTX) Listen to this Section


$6.74
-0.2200 ( -3.16% ) 216.9K

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Market Data


Open


$6.74

Previous close


$6.96

Volume


216.9K

Market cap


$290.81M

Day range


$6.69 - $7.10

52 week range


$6.30 - $35.06

Insider Ownership Transactions

Total Amount Purchased: 1,139,027.00 | $ 7,677,041.98

Date Type Amount Purchased Purchaser
2024-06-10 Sale -9636.00 Walker Karen Marie
2024-05-29 Sale -10870.00 Jones Ryan Alexander
2024-02-14 Buy 2713868.00 Bain Capital Life Sciences Investors, LLC
2024-02-14 Sale -3787940.00 SEIDENBERG BETH C
2024-02-14 Sale -4523924.00 Cohen Fred E
2024-02-14 Buy 4523924.00 Vida Ventures, LLC
2024-02-14 Sale -3787940.00 Westlake BioPartners Fund I, L.P.
2024-02-13 Buy 3216119.00 GILEAD SCIENCES, INC.
2024-02-12 Buy 2805426.00 Northpond Ventures III GP, LLC

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 12 Aug 12, 2024
10-q Quarterly Reports 68 Aug 12, 2024
8-k 8K-related 12 Jul 15, 2024
8-k 8K-related 43 Jun 14, 2024
4 Insider transactions 1 Jun 10, 2024
4 Insider transactions 1 May 29, 2024
10-q Quarterly Reports 68 May 14, 2024
8-k 8K-related 12 May 14, 2024
10-k Annual reports 30 Mar 26, 2024
8-k 8K-related 2 Mar 26, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.